Although peak NfL levels appear to be better at differentiating GBS from CIDP in our cohort than peripherin, a binomial regression of the two biomarkers improves model specificity, suggesting that peripherin does have a role alongside NfL in differentiating acute from chronic inflammatory neuropathies. The gene discussed is PRPH; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.